Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Altinicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 6/20 | 1.00 |
| ▸ | CHRNA4 known ✓ | P43681 | 5/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 6/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 5/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 4/20 | 1.00 |
| ▸ | CHRNA2 | Q15822 | 3/20 | 1.00 |
| ▸ | CHRNG | P07510 | 2/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 2/20 | 1.00 |
| ▸ | CHRND | Q07001 | 2/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.52 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | HTR3B | O95264 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Altinicline SCHEMBL1155706 | 1.00 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| Altinicline SCHEMBL194945 | 0.89 | CHRNA3 (0.79) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| Altinicline SCHEMBL3099334 | 0.89 | CHRNA3 (0.79) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| Altinicline SCHEMBL15253516 | 0.89 | CHRNA3 (0.79) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| Altinicline SCHEMBL3099328 | 0.89 | CHRNA3 (0.79) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| SCHEMBL6972915 | 0.84 | CHRNB4 (0.72) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| SCHEMBL13388063 | 0.82 | CHRNA3 (0.70) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| SCHEMBL6973153 | 0.82 | CHRNB4 (0.69) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| SCHEMBL7099210 | 0.82 | CHRNA3 (0.69) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| SCHEMBL6964032 | 0.81 | CHRNB4 (0.67) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240329053-A1 | A CELL-BASED METHOD FOR DETECTING POTENTIALLY PATHOGENIC AUTOANTIBODIES TO NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS | TZARTOS NEURODIAGNOSTICS (GR) | 2024-10-03 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-21 | — | — | US | claimed |
| EP-2858649-B1 | TREATMENT OF MOTOR AND MOVEMENT DISORDER SIDE EFFECTS ASSOCIATED WITH PARKINSON'S DISEASE TREATMENTS | PSYCHOGENICS INC (US) | 2019-10-23 | — | — | EP | claimed |
| EP-1126846-B1 | Use of a nicotine receptor agonist for the manufacture of a medicament for the treatment of obsessive compulsive disorder | CARLSSON A RESEARCH AB (SE) | 2003-08-06 | — | — | EP | claimed |
| US-20260146254-A1 | Enhancing Oligonucleotide Immunomodulatory Activity through Dianophore Long-Lasting Modification: Methods and Applications | SEGENA CORPORATION S.A. (UY) | 2026-05-28 | — | — | US | disclosed |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4704983-A2 | TREATMENT OF MEMORY LOSS WITH PHOSPHODIESTERASE INHIBITORS | Cyrano Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260041690-A1 | Treatment of Memory Loss with Phosphodiesterase Inhibitors | CYRANO THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4622674-A1 | ENHANCING OLIGONUCLEOTIDE IMMUNOMODULATORY ACTIVITY THROUGH DIANOPHORE LONG-LASTING MODIFICATION: METHODS AND APPLICATIONS | SEGENA CORPORATION S.A. (UY) | 2025-10-01 | — | — | EP | disclosed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | SWITCH BIO, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-1214062-A2 | METHOD OF TREATING DRY EYE DISEASE WITH NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Inspire Pharmaceuticals (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2002030405-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | WO | disclosed |
| WO-2001087288-A2 | METHOD OF TREATING VAGINAL DRYNESS WITH NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | INSPIRE PHARMACEUTICALS, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001080844-A2 | METHOD OF TREATING DRY EYE DISEASE WITH NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | INSPIRE PHARMACEUTICALS, INC. (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1126846-A1 | USE OF A NICOTINE RECEPTOR AGONIST IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER | A Carlsson Research AB (SE) | 2001-08-29 | — | — | EP | disclosed |
| US-6277855-B1 | STIMULATION OF MUCIN SECRETION IN THE LACRIMAL SYSTEM | INSPIRE PHARMACEUTICALS, INC. | 2001-08-21 | — | — | US | disclosed |
| WO-2000025783-A1 | USE OF A NICOTINE RECEPTOR AGONIST IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER | A CARLSSON RESEARCH AB (SE) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041690-A1 | Treatment of Memory Loss with Phosphodiesterase Inhibitors | PDE2A, PDE4A, PDE3A | CHRNB2 78/4885CHRNA4 133/4885CHRNA3 239/4885 |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | CHRNA5, CHRNA2, CHRNA4 | CHRNB2 11/4885CHRNA4 3/4885CHRNA3 9/4885 |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | CACNB2, CHRNA2, HCN3 | CHRNB2 5/4885CHRNA4 4/4885CHRNA3 9/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | CHRNB2 41/4885CHRNA4 76/4885CHRNA3 69/4885 |
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | EYA3, RB1, ALDH1A2 | CHRNB2 63/4885CHRNA4 353/4885CHRNA3 161/4885 |
| US-20260146254-A1 | Enhancing Oligonucleotide Immunomodulatory Activity through Dianophore Long-Lasting Modification: Methods and Applications | CD44, ADAR, TLR9 | CHRNB2 679/4885CHRNA4 1016/4885CHRNA3 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.